| Term 
 
        | What do the following cells secrete? (a) Alpha cells (b) Beta cells (c) D cells (d) PP F cells |  | Definition 
 
        | (a) Glucagon (b) Insulin  (c) Somatostatin (d) pancreatic polypeptide |  | 
        |  | 
        
        | Term 
 
        | What are the 3 effects of glucagon? |  | Definition 
 
        | Stimulates production of glucose in liver  (gluconeogenesis) Stimulates breakdown of glycogen  into  glucose in skeletal muscles and liver cells  (glycogenolysis) Stimulates breakdown of triglycerides in  adipose tissue and fatty acid release  (lipolysis) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 1. Accelerates glucose uptake and utilization by  cells 2. Stimulates glycogen formation (glycogenesis) 3. Stimulates triglyceride formation in adipose  tissue (lipogenesis) 4. Stimulates amino acid absorption and  protein synthesis |  | 
        |  | 
        
        | Term 
 
        | Normal blood glucose levels when  (a) fasting (b) 2 hours after meals (PP2) |  | Definition 
 
        | (a) 70-110 mg/dl (b)<180 mg/dl |  | 
        |  | 
        
        | Term 
 
        | Abnormal blood glucose – Hypoglycemia:  – Hyperglycemia:  • Impaired glucose tolerance:  • Diabetes mellitus:  |  | Definition 
 
        | - < 70 mg/dl - >110 mg/dl -110-180 g/dl >180mg/dl |  | 
        |  | 
        
        | Term 
 
        | Causes of secondary diabetes: |  | Definition 
 
        | Pancreatic disease: e.g., pancreatitis, tumor – Endocrine disease: e.g., Cushing’s syndrome – Drug induced: e.g., thiazide diuretics – Infection: e.g., congenital rubella |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | Clinical manifestations of DM: |  | Definition 
 
        | Polydipsia • Polyuria + nocturia • Glycosuria • Complications |  | 
        |  | 
        
        | Term 
 
        | Complications of DM • Acute: |  | Definition 
 
        | – Diabetic ketoacidosis (DKA) – Hyperosmolar non-ketotic  (HONK) coma  |  | 
        |  | 
        
        | Term 
 
        | Complications of DM Chronic:  |  | Definition 
 
        | Angiopathy: • Microangiopathy: – retinopathy - neuropathy - nephropathy • Macroangiopathy: – E.g., coronary artery disease (CAD) |  | 
        |  | 
        
        | Term 
 
        | Other complications of DM: |  | Definition 
 
        | infection - skin complications |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Diet control • Antidiabetic agents • Treatment of complications |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Insulin • Oral hypoglycemic agents |  | 
        |  | 
        
        | Term 
 
        | Indications of Insulin Therapy |  | Definition 
 
        | Type I diabetes • Type II diabetes: – Inadequate control by oral hypoglycemic agents – Stressful conditions: e.g., infection – During pregnancy  • Gestational diabetes |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | • Bovine • Porcine • Human recombinant: – Least antigenic – Standardized to 100 U/ml |  | 
        |  | 
        
        | Term 
 
        | Administration of source of insulin |  | Definition 
 
        | Injection: SC, IV, IM – Alternative methods: e.g., pump |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | Regular (crystalline) insulin |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | NPH (Neutral Protamine Hagedorn) insulin – Lente insulin: reasonably soluble zinc preparation |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Ultralente: poorly soluble zinc preparation |  | 
        |  | 
        
        | Term 
 
        | Mixed types (combinations): |  | Definition 
 
        | – Rapid onset & prolonged duration |  | 
        |  | 
        
        | Term 
 
        | Insulin Regimens  • Conventional therapy: |  | Definition 
 
        | One or two injections per day – Daily self monitoring of glucose  – Lower risk of hypoglycemia |  | 
        |  | 
        
        | Term 
 
        | Insulin regimens: Intensive therapy |  | Definition 
 
        | Multiple daily injections – Daily self monitoring of glucose and dose adjustment – Reduction in retinopathy, nephropathy, and  neuropathy – Higher risk of hypoglycemia (3-fold more than  conventional regimen) |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | Absorption of SC Insulin • Highly variable: |  | Definition 
 
        | Among different patients – Between doses in same patient |  | 
        |  | 
        
        | Term 
 
        | Factors affecting absorption of SC insulin: |  | Definition 
 
        | Blood flow to site of injection – Site of injection: • Abdomen > arm > buttock > thigh – Depth of injection – Exercise increases absorption – Massage of the area increases absorption |  | 
        |  | 
        
        | Term 
 
        | Alternatives to Insulin Injection (5) |  | Definition 
 
        | Insulin pumps • Insulin pens (insulin containing cartridges) • Inhaled insulin • Transdermal patches • Oral formulas (designed to resist insulin  digestion in the GIT) |  | 
        |  | 
        
        | Term 
 
        | 2 characteristics of Insulin pumps: |  | Definition 
 
        |   Indwelling catheter delivers basal insulin  • Patient can program device to modify delivery rate    |  | 
        |  | 
        
        | Term 
 
        | What is a promising alternative to insulin injection? |  | Definition 
 
        | Inhaled insulin  (Exubera) |  | 
        |  | 
        
        | Term 
 
        | Exubera: (a) Preparation (b) powder (c) delivery |  | Definition 
 
        | (a) Short - acting insulin preparation (b) fine dry powder (c) Non-invasive insulin delivery |  | 
        |  | 
        
        | Term 
 
        | What enters the blood faster? Inhaled insulin or SC injection? Where must the drug reach? |  | Definition 
 
        | Inhaled insulin Alveoli in the lung |  | 
        |  | 
        
        | Term 
 
        | Complications of Insulin Therapy 
     |  | Definition 
 
        |   Hypoglycemia → most dangerous – Insulin allergy → rare with human insulin  – Insulin resistance    |  | 
        |  | 
        
        | Term 
 
        | Complications of Insulin Therapy Local |  | Definition 
 
        |   Lipoatrophy – Hypertrophy    |  | 
        |  | 
        
        | Term 
 
        | Oral Hypoglycemic Agents (5) |  | Definition 
 
        |   Sulfonylureas • Biguanides  • Meglitinides  • Thiazolidinediones (TZDs, glitazones)  • Alpha-glucosidase inhibitors    |  | 
        |  | 
        
        | Term 
 
        | Mechanism of action of sulfonylureas: |  | Definition 
 
        |   Inhibit K channels on β-cell → causing depolarization → ↑ calcium entry → ↑ insulin release   |  | 
        |  | 
        
        | Term 
 
        | Where do sulfonylureas potentiate insulin action? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What do sulfonylureas require? Which diabetes are they useful for? |  | Definition 
 
        | Functional B cells to work Only useful for type 2 not type 1 |  | 
        |  | 
        
        | Term 
 
        | What do sulfonylureas bind to? (b) metabolised (c) excreted |  | Definition 
 
        | (a) Plasma proteins (b) Liver (c) Kidney |  | 
        |  | 
        
        | Term 
 
        | Exaggerated effects of sulfonylureas are in: |  | Definition 
 
        | (a) Elderly (b) Renal disease (c) Liver disease |  | 
        |  | 
        
        | Term 
 
        | Where are sulfonylureas contraindicated? |  | Definition 
 
        | Pregnancy. They can cross the placenta and have teratogenic effects. |  | 
        |  | 
        
        | Term 
 
        | Which drugs increase hypoglycemic effects? |  | Definition 
 
        |   NSAIDs, coumarins, alcohol, MAO inhibitors, some antibacterials (sulfonamides, chloramphenicol) – Cimetidine (inhibits metabolism)    |  | 
        |  | 
        
        | Term 
 
        | Which drug inhibits insulin release? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What can mask the symptoms of hypoglycemia? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | First generation sulfonylureas (least potent) |  | Definition 
 
        | tolbutamide, chlorpropamide |  | 
        |  | 
        
        | Term 
 
        | 2nd generation sulfonylureas: |  | Definition 
 
        | Glipizide, Glibenclamide, Ggliclazide |  | 
        |  | 
        
        | Term 
 
        | 3rd generation sulfonylureas: |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Side effects of sulfonylureas: |  | Definition 
 
        | Hypoglycemia (esp. chlorpropamide) Gi disturbances Jaundice Allergic skin reactions   |  | 
        |  | 
        
        | Term 
 
        | Why does chlorpropamide have more side effects? |  | Definition 
 
        | More side effects especially hypoglycemia because prolonged duration of action. |  | 
        |  | 
        
        | Term 
 
        | Mechanism of action of biguanides: |  | Definition 
 
        | Decrease gluconeogenesis in liver Increase glucose uptake in skeletal muscles |  | 
        |  | 
        
        | Term 
 
        | Indications of biguanides: |  | Definition 
 
        | First choice drug in patients with Type 2 DB Can be combined with sulfonylureas and insulin |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Do not cause hypoglycemia as they do not alter insulin levels. |  | 
        |  | 
        
        | Term 
 
        | Side effects of biguanides: |  | Definition 
 
        | Anorexia: Dose dependent can be severe Nausea, diarrhea, metallic taste Lactic acidosis (acidification of blood) |  | 
        |  | 
        
        | Term 
 
        | Contraindications of biguanides: |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What is the only approved form of biguanides? What are its 2 forms? |  | Definition 
 
        | Metformin (dimethylbiguanides)     
 
Glucophage™ 
   
 
Glucophage XR™ (extended-release tablets)     |  | 
        |  | 
        
        | Term 
 
        | What are meglinitides? What are they similar to? Duration of action? |  | Definition 
 
        | Short acting insulin secretagogues. Similar in action to sulfonylureas. Half life is 1 hour. |  | 
        |  | 
        
        | Term 
 
        | Indications of meglitinides: |  | Definition 
 
        | Type 2 DM. Can be combined with metformin. |  | 
        |  | 
        
        | Term 
 
        | Side effects of meglitinides: |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Examples of meglitinides:   |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Mechanism of action of TZDs: |  | Definition 
 
        |     
 
Activate a transcription regulator, PPARγ (peroxisome proliferator-activated receptor gamma) →  
modulate lipogenesis in adipocytes 
   
 
improve glucose uptake in skeletal muscles    
 
reverse insulin resistance      |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   Type 2 DM  – Alone or combined with metformin, sulfonylurea    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Congestive heart failure Myocardial ischemia May cause liver injury (monitor liver f unction) |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | Alpha-glucosidase Inhibitors |  | Definition 
 
        | Inhibits α-glucosidases in intestine → reduces absorption of carbohydrates •
 Not absorbed from intestine
 •
 Control post-prandial glucose levels not adequately controlled by diet and sulfonylureas
 •
 Side effects:
 –
 GI upset and flatulence
 •
 E.g., Acarbose
 |  | 
        |  | 
        
        | Term 
 
        | What do you use for (a) Impaired insulin secretion (b) Glucose uptake and utilisation |  | Definition 
 
        | (a) Sulfonylureas and meglitinides (b) Metformin and TZDs |  | 
        |  |